Parexel has expanded its alliance network for early-phase research by teaming up with University Hospitals Bristol National Health Service Foundation Trust (UH Bristol), one of the UK’s largest specialist teaching and research hospital trusts.
The alliance network complements the US-based biopharmaceutical services company’s hospital-based early-phase units in Berlin (Germany), London (UK), Bloemfontein (South Africa) and, in its home market, Baltimore and Glendale.
Parexel’s Early Phase business helps clients with the design and execution of early-phase studies from first-in-human through to proof-of-concept.
According to Sy Pretorius, corporate vice president and worldwide head of Early Phase, UH Bristol is an “ideal” alliance for Parexel due to the trust’s “experience in conducting clinical research, access to substantial patient populations, and work across multiple therapeutic areas”.
Collaborative and consultative
UH Bristol is the biggest provider of medical and dental teaching in South West England, as well as a leading research centre and one of the largest acute NHS Trusts in the UK, Parexel noted. It delivers more than 100 different clinical services from nine hospitals in the heart of Bristol.
